Healthcare Industry News: Bladder Cancer
News Release - May 30, 2008
NCCN Previews Chemotherapy Order Templates(TM)FORT WASHINGTON, Pa.--(HSMN NewsFeed)--An initial set of NCCN Chemotherapy Order Templates™, peer-reviewed and evidence-based chemotherapy regimens with indications, doses, and schedules and routes of administration will be previewed at the upcoming American Society of Clinical Oncology (ASCO) meeting to be held May 31 to June 2, 2008.
The Templates can enhance patient safety by helping clinicians standardize patient care, reduce medication errors and anticipate and manage adverse events. They also include appropriate antiemetic and supportive care treatments, monitoring and safety patterns and supporting references. All clinical information in the Templates is derived from the recommendations of the NCCN Clinical Practice Guidelines in Oncology™ and the NCCN Drugs & Biologics Compendium™.
Access to the first set of NCCN Chemotherapy Order Templates™ will be provided via a flash-stick that can be obtained at the NCCN ASCO exhibit booth number 23015 and will include templates for the treatment of:
- Bladder Cancer
- Chronic Myelogenous Leukemia
- Kidney Cancer
- Prostate Cancer
For more information on the NCCN Chemotherapy Order Templates™, please contact Thomas Mitchell at 215-690-0245 or visit www.nccn.org.
About the National Comprehensive Cancer Network
The National Comprehensive Cancer Network (NCCN), a not-for-profit alliance of 21 of the world’s leading cancer centers, is dedicated to improving the quality and effectiveness of care provided to patients with cancer. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. As the arbiter of high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers. The primary goal of all NCCN initiatives is to improve the quality, effectiveness, and efficiency of oncology practice so patients can live better lives.
For more information, visit www.nccn.org.
The NCCN Member Institutions are: City of Hope, Los Angeles, CA; Dana-Farber/Brigham and Women’s Cancer Center | Massachusetts General Hospital Cancer Center, Boston, MA; Duke Comprehensive Cancer Center, Durham, NC; Fox Chase Cancer Center, Philadelphia, PA; Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT; Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance, Seattle, WA; Arthur G. James Cancer Hospital & Richard J. Solove Research Institute at The Ohio State University, Columbus, OH; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL; Memorial Sloan-Kettering Cancer Center, New York, NY; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL; Roswell Park Cancer Institute, Buffalo, NY; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine, St. Louis, MO; St. Jude Children’s Research Hospital/University of Tennessee Cancer Institute, Memphis, TN; Stanford Comprehensive Cancer Center, Stanford, CA; University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, AL; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; UNMC Eppley Cancer Center at The Nebraska Medical Center, Omaha, NE; The University of Texas M. D. Anderson Cancer Center, Houston, TX; and Vanderbilt-Ingram Cancer Center, Nashville, TN.
Source: National Comprehensive Cancer Network
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.